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To analyze the pattern and appropriateness of pain medications in older adults receiving
home care.
Methods
We performed a prospective cross-sectional study in patients�65 years old having chronic
pain and receiving home care in Berlin, Germany. Data on prescribed pain medications
were collected using self-reported information, nursing documents, and medication plans
during interviews at home. Pain intensity was determined with the numeric rating scale
(NRS) and the Pain Assessment In Advanced dementia (PAINAD) scale. The Pain Medica-
tion Appropriateness Scale score (SPMAS) was applied to evaluate inappropriateness (i.e. a
score�67) of pain medication.
Results
Overall 322 patients with a mean age of 82.1 ± 7.4 years (71.4% females) were evaluated.
The average pain intensity scores during the last 24 hours were 5.3 ± 2.1 and 2.3 ± 2.3 on
NRS and PAINAD scale (range 0–10, respectively). Sixty (18.6%) patients did not receive
any pain medication. Among the treated patients, dipyrone was the most frequently pre-
scribed analgesic (71.4%), while 50.8% and 19.1% received systemic treatment with opioids
and non-steroidal anti-inflammatory drugs, respectively. The observed median SPMAS was
47.6 (range 0–100) with 58 (18.0%) of patients achieving appropriate values. Half of the
patients were treated with scheduled, while 29.9% were only treated with on-demand medi-
cations. Cognitive status had no effect on appropriateness of pain treatment.
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Conclusions
We observed substantial deficits in dosing patterns and appropriateness of pain medication
in older adults with pain receiving home care. This applied to both patients with and without
severe cognitive impairment.
Introduction
The global population has experienced a demographic change over the last century towards
an aging population [1]. In Germany, an estimated 3.4 million individuals are in need of
care and the majority of them (81%) are more than 65 years old, while 35% are at least 85
years old [2]. For this elderly population, pain represents a significant problem due to the
high prevalence of musculoskeletal disorders, cancer, neuropathy and other medical condi-
tions for which pain is a major symptom [3]. The prevalence estimates of chronic pain in
the general population in Europe range from 12% to 30%, while in Germany a rate of 17%
has been previously reported [4]. A more recent meta-analysis reported that about 62% of
the population over the age of 75 years suffered from chronic pain in the UK indicating that
the burden of chronic pain increases in line with aging [5]. On the other hand, a previous
study indicated that there is an age-dependent discrepancy between the prevalence of
chronic pain and pain interference or suffering from chronic pain [6]. Nevertheless, in the
elderly it is estimated that about 70% of elderly individuals in home care are suffering from
pain [7]. The problem is further complicated in those with cognitive impairment who are
mostly incapable of communicating their own symptoms, which hinders appropriate man-
agement of pain in this population [8].
While pain itself is not a disease, rather a symptom to a multitude of underlying health
disorders, chronic pain is regarded by some as a disease in its own right [9]. The implemen-
tation of a separate diagnostic code for chronic pain according to the newest International
Classification of Diseases (ICD-11) underlines the need for better care for patients with
chronic pain [10].
Uncontrolled pain substantially affects daily activities such as sleeping, housework and
social relationships, and despite a plethora of available analgesic drugs, pain remains inade-
quately treated in most elderly patients [11, 12]. On the other hand, improved pain relief can
positively reactivate a person’s physical and mental condition [13].
The elderly population is challenging in terms of its complexity and heterogeneity where
comorbidity and polypharmacy complicate frailty [14]. Thus, improper use of pain medica-
tions and polypharmacy increases the risk of drug interactions and developing adverse drug
reactions in the elderly [15]. The latter accounts for a great burden of disease in these patients
including the need for hospital admission [16]. Hence, a recent meta-analysis showed that
among patients admitted to hospital because of adverse drug reactions, non-steroidal anti-
inflammatory drugs (NSAIDs) were frequently related to these admissions (percentages range
from 2.3 to 33.3%) [16]. Optimal medical management and nursing care in pain treatment
are thus essential to reduce morbidity and costs in long-term care. Nevertheless, to implement
appropriate pharmacologic pain management in practice remains a challenging task.
We set out to assess the pattern of prescribed pain medications and their appropriateness in
older adults receiving home care. We performed a prospective cross-sectional study in Berlin,
Germany, and included patients independently from their cognitive status; thus patients with
cognitive impairment were also enrolled.
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Methods
Design and setting
The current analysis is a pre-specified analysis of the recently completed ACHE study (“Devel-
opment of a Model for PAin Management in Older Adults ReCeiving Home CarE”) in Ger-
many. ACHE is an observational cross-sectional study conducted in the home care setting in
Berlin, Germany, from May 2017 to April 2019. The study complies with the declaration of
Helsinki and was approved by the ethical committee of the Charite´, Universita¨tsmedizin Berlin
(EA1/368/14). Written informed consent was obtained by all the patients or their legal guard-
ians in case of cognitive impairment.
Study population
Older adults receiving home care were mainly recruited through ambulatory nursing services
(Fig 1) and were included if they met the following criteria: 1) aged 65 years or older; 2) suffer-
ing from chronic pain (� 3 months); 3) live at their own homes and 4) in need of care accord-
ing to the legal regulations in Germany. Importantly, patients were enrolled independently
from their cognitive status. Thus, we also included patients with cognitive impairment. There
were 82 (15%) of 546 ambulatory care stations in Berlin that volunteered to take part in the
study. The cognitive state of all patients was assessed using the Mini Mental Status Examina-
tion (MMSE) [17].
Data collection
Data were obtained through face-to-face interviews in the patients’ own homes by five trained
research assistants with different educational and professional qualifications including back-
grounds in pharmacy, medical education, social science, nursing, or occupational therapy.
Data on pain characteristics, pain management strategies, demographics as well as the level
of care were collected and were based primarily on patients’ self-report, caregiving relatives,
nurses and, if available, medication plans (Table 1). Drug-related data were systematically
obtained by scanning medication packages using barcode scanners and the Instrument for
Database-assisted Online recording for Medication (IDOM) [18]. The latter is based on detailed
classification data provided by the AOK Research Institute (WIdO) that were updated on a
monthly basis. All information regarding the active ingredients, the anatomical therapeutic
chemical (ATC) classification, dosage, the mode of administration, “over the counter” (OTC)-
drugs and nutritional supplements were recorded. Moreover, the investigators asked how
patients obtained their drugs (e.g. by prescription, doctor’s recommendation or self-medica-
tion), the frequency of administration (scheduled or on-demand) as well as the duration of
treatment. The gathered information about medications, diagnosis, and pain intensity, as well
as pain relief by medications by the physician were utilized later to assess the appropriateness
of pain management.
Instruments and measures
Pain management was evaluated by using the Pain Medication Appropriateness Scale (i.e.
PMAS) originally designed to detect problems in pain therapy in nursing homes [21]. The
PMAS is a valid tool to analyze the pharmacological treatment of pain. To check for scale reli-
ability, Cronbach´s coefficient alpha was calculated for PMAS [22]. This scale consists of ten
items allocated to five main domains (appropriate medication for pain syndrome, scheduled
dose interval, titration of medication to severity of pain including the pain management index
(PMI), constipation prevention, and exclusion of geriatric high-risk drugs). In a previous
Pain medication in home care
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Fig 1. Flowchart—Recruitment strategy and methodical approach. SPMAS, Score on the Pain Medication Appropriateness Scale.
aE.P.S. GmbH
is a service in Germany that provides advices to family caregivers regarding home care related issues.
https://doi.org/10.1371/journal.pone.0229229.g001
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study, the PMAS was successfully adapted for the evaluation of pain medication management
in Germany [23]. For the evaluation of PMAS, pain intensity was assessed using numeric rat-
ing scales (NRS) for pain as implemented within the Brief Pain Inventory (BPI) [24] in patients
without cognitive impairment. In patients with an MMSE value <10 or in whom NRS could
not be evaluated for other reasons, the Pain Assessment In Advanced Dementia (PAINAD)
scale [25] was applied. The corresponding validated German transcript for the PAINAD scale
was used [26]. The BPI includes four NRS ranging from 0 (no pain) to 10 (worst imaginable
pain) to asses four items of pain intensity (worst pain, lowest pain, average pain, current pain)
over the past 24 hours.
The German PAINAD scale consists of five items that focus on characteristic behavior due
to pain in patients with advanced dementia as a physical indication of pain suffering (breath-
ing, negative vocalization, facial expression, body language and consolability). For each item
considering different behavioral patterns, there is a scale from 0 to 2 and total scores between 0
and 10 are possible.
A checklist for special types of pain was also applied. Functional status was evaluated by the
Barthel-Index (BI) [27, 28].
Only medications that were prescribed by the treating physicians were considered for
PMAS analysis, including both scheduled and on-demand medications; dosing intervals were
also considered. Furthermore, we adapted the PMAS according to current national guidelines
of pain management as well as high risk drugs avoided in geriatric patients [29, 30] (S1 Table).
In addition, we formulated a four-class categorization of the PAINAD-score using boxplots
and substantiated our approach by the Receiving Operating Characteristic (ROC)-curve analy-
sis (S2 Table and S1 Fig) [31].
Table 1. Patient characteristics.
Characteristics Full study population PMAS population
Total N = 355 Women N = 254 (71.5%) Men N = 101 (28.5%) Total N = 322 Women N = 230 (71.4%) Men N = 92 (28.6%)
Age (years) 82.2 ± 7.5 83.0 ± 7.1 80.4 ± 8.4 82.1 ± 7.4 82.7 ± 6.9 80.4 ± 8.3
Care level (%)a
1 11.3 9.8 14.8 12.4 10.9 16.3
2 44.8 45.7 42.6 46.6 48.3 42.4
3 21.1 20.1 23.8 20.8 19.6 23.9
4 12.7 13.8 9.9 10.9 11.3 9.8
5 7.3 7.1 7.9 6.8 6.9 6.5
nd 2.8 3.5 1.0 2.5 3.0 1.1
MMSE (%)b,c
0–17 points 22.6 23.7 19.8 18.9 19.5 17.4
18–23 points 15.8 15.4 16.8 15.8 17.0 13.0
24–30 points 61.6 60.9 63.4 65.3 63.5 69.6
Barthel indexd,e 66.7 ± 27.5 66.9 ± 26.5 66.3 ± 29.9 68.7 ± 26.4 69.4 ± 24.9 67.0 ± 29.8
PMAS, Pain Medication Appropriateness Scale; nd, not determined; MMSE, Mini Mental State Examination.
aAccording to § 15 SGB XI, the level of care is based on the degree of self-dependence and ranges from 1 (lowest degree) to 5 (most severe impairment with special
requirements for nursing care).
bThe MMSE-score was calculated for 354 individuals.
cAccording to the MMSE classification [19]: 0–17 (severe cognitive impairment), 18–23 (mild cognitive impairment), 24–30 (no cognitive impairment).
dThe Barthel-index was calculated for 349 individuals of the total population and for 319 of the PMAS population.
eThe motor function restriction is graded by the Barthel index into [20]: 0–15 (very severe), 20–30 (severe), 40–55 (intermediate severe), 60–75 (intermediate), 80–95
(low) and 100 (no or minimal functional impairment).
https://doi.org/10.1371/journal.pone.0229229.t001
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Each item of the PMAS was assessed if it applied to the patient’s individual situation. As a
result, there are different maximum points possible. The final PMAS-score (i.e. SPMAS) reflects
a percentage considering the possible points (Spossible), as well as the applicable points (Stotal)






An SPMAS�67 value indicates inappropriate pain medication as suggested [21]. In individ-
uals in whom self-reported pain assessment was not feasible, a score of�1 on the PAINAD
scale indicated probable pain.
Data analysis
Descriptive statistics were used to describe demographics of patients and variables related to
pain- and medications. Data were analyzed using IBM SPSS Statistics, version 25 (IBM Corp,
Armonk, NY). The analysis of SPMAS is based on an adapted version of the reported German
version of the PMAS [23]. The distribution of variables was checked using Shapiro-Wilks test.
For data without normal distribution, the non-parametric Mann-Whitney U test or Kruskal-
Wallis H test were used as appropriate. Thus, the latter was used to compare SPMAS values of
the different subgroups related to the mode of drug intake (only on demand, only scheduled,
both, none) and was followed by Dunn-Bonferroni test for posthoc analysis. Data for SPMAS
were presented as median and range. Spearman’s correlation and Chi-squared test were con-
ducted to check associations between patients‘characteristics and the SPMAS. Statistical signifi-
cance was determined with an alpha value of 0.05.
Results
Study participants
A total of 355 patients (mean age 82.2 ± 7.5 years, 71.5% females) met the formal inclusion
criteria of the overall ACHE study; data of 322 patients (mean age 82.1 ± 7.4 years, 71.4%
females) were available for analysis of appropriateness of pain medication, i.e. PMAS popula-
tion (Table 1). Patients were excluded because of missing data regarding medication, diagnosis
or some other aspects that are necessary to calculate SPMAS. The majority of patients (46.6%)
received the second level of care, while for 2.5% the level of care was not determined (Table 1).
No or only mild cognitive impairment was observed in 261 (81.1%) patients, while 18.9% had
severe cognitive impairment (MMSE�17 points). The mean Barthel index was 68.7 ± 26.4. All
patients suffered from chronic pain and had an average pain intensity score of 5.3 ± 2.1 on the
NRS (range 0–10) during the last 24 hours. The corresponding score was 2.3 ± 2.3 on the PAI-
NAD scale (range 0–10) in patients with cognitive impairment (n = 64). Overall 211 (65.5%)
patients reported current pain at the time of interviewing with an average intensity of 5.7 ± 1.9
on the NRS and 3.0 ± 2.2 on the PAINAD scale in the last 24 hours. The mean score for worst
pain that was obtained in patients with current pain and without cognitive impairment over
the past 24 hours was 6.9 ± 2.1. Almost half of the patients (n = 155) have had chronic pain for
at least 10 years. Low back pain (75.8%), osteoarthritis (67.2%) and neuropathic pain (57.1%)
were the most frequently recorded underlying pain conditions, besides other diseases such as
headache (32.9%), rheumatoid arthritis (14.2%) and urarthritis (12.9%).
Pattern of pain medications
Overall sixty (18.6%) patients did not receive any pain medication and from the 211 patients
who reported having current pain during the interview, 37 (17.5%) received no prescribed
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pain medication. About half of the patients (162/322) were treated with systemically adminis-
tered scheduled analgesics. About a quarter of patients (81/322) were only treated with sched-
uled and 29.9% (96/322) received only on-demand medications.
Dipyrone was most frequently prescribed (Fig 2) in a total of 187 (71.4%) of treated patients
of whom 81 (43.3%) patients received dipyrone as monotherapy. The second most frequently
prescribed drug was ibuprofen in 38 (14.5%) of treated patients. Only 50 (19.1%) of all treated
patients received systemic treatment with any NSAID, either as scheduled or as on-demand
medication. Overall 133 (50.8%) patients received treatment with systemic opioids most fre-
quently as scheduled treatment (n = 118), but only 45.8% of the latter were prescribed addi-
tional treatment with laxatives for constipation prophylaxis.
Fig 2. Numbers of individuals with prescribed analgesics among the PMAS population. PMAS, Pain Medication Appropriateness Scale.
https://doi.org/10.1371/journal.pone.0229229.g002
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Appropriateness of pain medications
The observed median SPMAS was 47.6 (range 0–100). The PMAS was reliable with a value of
0.83 for Cronbach´s alpha. According to the suggested cutoff of�67 [21], only 58/322 (18.0%)
of patients received adequate pain medication. SPMAS in patients with prescribed analgesics
was significantly higher (median: 53.3 [range 0–100]) than in subjects without any pain medi-
cation (median: 6.7 [range 0–66.7], Mann Whitney test, U = 1100.5, p< 0.001). Patients who
received only on-demand pain medication achieved lower SPMAS values compared to patients
treated only with scheduled analgesics (median: 33.3 [range 0–100] vs. 50.0 [range 22.2–83.3],
Kruskal-Wallis H test, H = 197.3, p< 0.001). Patients managed by both scheduled and on-
demand medication (n = 84) obtained the highest SPMAS (median: 71.4 [44.4–93.3], Kruskal-
Wallis H test, p < 0.001). Age, sex, cognitive state, school education, professional qualification,
functional state, and pain intensity did not significantly affect appropriateness of pain
medication.
We observed a moderate correlation between the number of prescribed analgesics and
SPMAS (r = 0.672; p< 0.001). Patients who achieved an SPMAS�67 were treated with an average
of 1.1 ± 0.8 (range 0–5) analgesic drugs, while patients with an SPMAS >67 received 2.1 ± 0.8
(range 1–4) medications. A total of 134 (51.1%) patients received only one analgesic, the
majority of them had an SPMAS�67. Nevertheless, there were 10/58 (17.2%) patients who
were adequately treated with monotherapy (Fig 3).
Discussion
In the current cross-sectional study, we identified several important deficits in pain medication
treatment in older patients receiving home care in Germany. First of all, 18.6% of patients with
a history of chronic pain did not receive any pain medication. Secondly, a substantial number
of patients were, in contrast with guideline recommendations [32], only treated with either
scheduled (25.2%) or on-demand medications (29.9%). This is important against the back-
ground of the history of chronic pain and intensity of current pain as observed during the last
24 hours in our cohort of patients. According to the MOBILIZE Boston study [33], about 30%
of community-living older adults with moderate to severe pain were also inadequately treated,
while 50% did not receive any pain medication [33]. The latter finding might be explained by
the relative high ratio of patients with very mild to mild pain enrolled in this study [33]. Roy
et al. reported in agreement with our current findings, that 16% of institutionalized elderly
patients with pain did not receive treatment with analgesics [34]. We also found in a previous
study in the nursing home setting in Germany, that 20.6% of residents with chronic pain
received no treatment with pain medications [35].
In agreement with previous findings in Germany [23, 35], dipyrone was by far the most
frequently prescribed analgesic in the current study. Despite the well-known risk of agranulo-
cytosis associated with dipyrone [36], the use of this drug seems well justified particularly in
the vulnerable elderly population, because of its favorable overall risk-benefit profile as com-
pared to NSAIDs [37, 38]. Although ibuprofen was the second most frequently prescribed
drug in our study, the overall prescription rate of systemic NSAIDs was relatively low (19.1%).
Their use is rated negatively in the evaluation of the appropriateness of pain medication in the
PMAS tool when prescribed as scheduled medication for a period longer than four weeks.
Furthermore, according to the Fit fOr The Aged (FORTA) List, NSAIDs should be generally
avoided in the elderly [30]. However, the use of acetaminophen, that is often preferred in
elderly patients due to its better safety profile [39], was also very low (5.0%). The latter could
be related to the fact that acetaminophen prescriptions in Germany are only reimbursed by
health insurances in patients suffering from severe pain and who are treated with opioids [40].
Pain medication in home care
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On the other hand, a substantial fraction (50.8%) of treated patients in our study was treated
with opioids. This could be ascribed to the observed high prevalence of patients with osteoar-
thritis, low back pain and neuropathic pain in whom opioids are often recommended [32].
However, the use of opioids for persistent pain is not without limitations particularly in the
treatment of older adults because of changes in their pharmacodynamic and pharmacokinetic
profile that may require dose adjustments [41]. Their long-term use may result in serious
adverse effects such as sedation, impaired balance and falls [41] in the vulnerable elderly
population exposed to polypharmacy [42].
When considering appropriateness of pain medication, less than one fifth (18%) of patients
received adequate pain treatment according to the suggested SPMAS cutoff value>67 [21]. Our
results are thus consistent with a corresponding study in the nursing home setting in Germany
that reported also deficits in pain treatment, although with a somewhat higher percentage of
patients (i.e. 24%) receiving appropriate treatment [23, 43]. A more recent study by Rabenberg
et al. substantiated our results by reporting deficits in pain treatment in the elderly [44]. In
their study, one out of ten older patients had a problem (under- or over-treatment) with pain
medications [44].
One strength of our study is related to the fact that we included also patients with severe
cognitive impairment (18.9%). This is in contrast to previous studies that either included only
a very small number of these patients [21] or excluded patients with moderate to severe
Fig 3. Number of analgesics per patient with respect to the appropriateness of pain medication. SPMAS, Score on the Pain Medication
Appropriateness Scale.
https://doi.org/10.1371/journal.pone.0229229.g003
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cognitive impairment [33] or dementia [45]. In order to assess the appropriateness of pain
medication in the patients with severe cognitive impairment, we used a four-class categoriza-
tion of the PAINAD-score to assess pain severity in this group of patients with a cutoff value
of 1 for mild pain (S3 Table). In the literature, a cutoff score of 2 on the PAINAD scale indi-
cates likely pain in patients with dementia, nevertheless, pain cannot be ruled out with a score
less than 2 for cognitively impaired individuals [46].
The observed positive correlation between the number of analgesics and SPMAS in the cur-
rent study is not surprising. A combination of two or more analgesics with complementary
mechanisms of action is projected to provide greater pain relief [32]. However, this does not
always imply that patients with the highest number of analgesics are treated best. It is equally
important to consider the class of drug in relation to the pain condition, the dosage, dosing
interval and the mode of application that also affect appropriateness within the evaluation
using PMAS. Indeed, there were patients in our sample treated with analgesic monotherapy
who reached the threshold for appropriate treatment (SPMAS >67). In addition, the combined
prescription of fast-onset, short-acting, on-demand analgesics with scheduled analgesics for
breakthrough pain is useful for optimal pain control [32]. This is corroborated by our finding
where patients treated with both scheduled and on-demand analgesics reached the highest
SPMAS. In analogy to regularly-administered medications, clear information regarding the
dose (initial and maintenance), the dosing interval and the duration of treatment should be
provided to patients when on-demand medications are prescribed [47].
As a case in point, we noticed that for 40.6% of prescribed on-demand analgesics, the dos-
ing interval was unknown. In these cases, we could not assess whether these analgesics were
adequately dosed by physicians. As a result, no additional points for adequate dosing intervals
were considered during evaluation.
Our study has some limitations. First, we analyzed only a relatively small sample because
access to this study population is very difficult to achieve in Germany. Second, the patients
were interviewed/observed only once, i.e. at a single occasion. Third, no interrater reliability
validity was done in our study. However, interrater reliabilities in our previous studies using
a similar overall approach were found to be satisfactory and highly significant [23, 35]. The
PMAS has also some limitations as previously pointed out [21, 23, 35]. Thus, in the calculation
of the SPMAS, non-pharmacological pain treatment is not considered. The potential of this
treatment modality should not be underestimated, especially in the elderly where side effects
of medications, drug-drug interactions, and comorbidities can impede the use of pharmaco-
logical treatments [48]. The combination of non-pharmacological and pharmacological pain
management is important for effective pain relief [14, 49]. Furthermore, no points are consid-
ered for treatment with co-analgesic drugs. Although co-analgesics are in general not primarily
indicated to treat pain, they are efficacious when combined with other analgesics [32, 50] and
may also be prescribed as monotherapy for special pain syndromes [32]. Nevertheless, the
PMAS tool is best known for its reliability and flexibility [43], whereby items could be elimi-
nated during assessment if they do not apply to individual patients. Accordingly, we modified
this scale in agreement with current recommendations regarding the use of cannabinoids in
the treatment of chronic pain [51, 52]. In addition, a moderate to high level for scale reliability
for the PMAS was indicated by a Cronbach´s alpha value of 0.83 [22].
Conclusions and implications
We observed substantial deficits related to lack of treatment, inadequate dosing patterns and
overall high frequency of inappropriate use of pain medications in older adults with pain
receiving home care. Therefore, interventional strategies to improve treatment by
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implementing a multidisciplinary network approach involving physicians, pharmacists, nurses
and patients, possibly supported by modern eHealth tools [53] is highly warranted.
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